Neuron Specific Enolase Concentration Is Increased in Serum and Decreased in Platelets of Patients with Active Systemic Sclerosis

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2606-2612

  Massabki, Paulo S ^a,b   Silva, Neusa P ^a,b   Lourenço, Dayse M ^a,c   Andrade, Luis E C ^a,b,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rheumatology Division   (Brazil)

^c Hematology Division

^d Rua Botucatu   (Brazil)

Author keywords

Neuron specific enolase; Platelet activation; Systemic sclerosis; Tumor markers

Indexed keywords

NEURON SPECIFIC ENOLASE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0347479259     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Farghali SA. Tumor markers in gynecologic cancer. Gynecol Obstet Invest 1992;34:65-72.
2. Cooner WH. Definition of the ideal tumor marker. Urol Clin North Am 1993;20:575-9.
3. Pandha HS, Waxman K, Sikora K. Tumour markers. Br J Hosp Med 1994;51:297-303.
4. Azis JK. Tumor markers: Current status and future applications. Scand J Clin Lab Invest 1995;55:153-5.
5. Azis JK. Tumor markers: Reclassification and new approaches to evaluation. Adv Clin Chem 1999;33:169-99.
6. Bates SE. Clinical applications of serum markers. Ann Intern Med 1991;115:623-38.
7. Shimomura C, Eguchi K, Kawakami A, et al. Elevation of a tumor associated antigen CA 19-9 levels in patients with rheumatic diseases. J Rheumatol 1989;16:1410-5.
8. Moncayo R, Moncayo H. Serum levels of CA 125 are elevated in patients with active systemic lupus erythematosus. Obstet Gynecol 1991;77:932-4.
9. Nyberg P, Söderblom T, Petterson T, Riska H, Klockars M, Linko L. Neuron-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Thorax 1996;51:92-4.
10. Moore BW, McGregor T. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem 1965;240:1647-53.
11. Marangos PJ, Campbell IC, Schmechel DE, Murphy DL, Goodwin FK. Blood platelets contain a neurone-specific enolase subunit. J Neurochem 1980;34:1254-8.
12. Day INM, Thompson RJ. Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 14-3-3 protein in circulating human blood cells. Clin Chim Acta 1984;136:219-28.
13. Cooper EH. Neuron-specific enolase. Int J Biol Markers 1994;4:205-10.
14. Carney DN. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982;1:583-5.
15. Cooper EH, Splinter TAW. Neuron-specific enolase (NSE): a useful marker in small-cell lung cancer. Lung Cancer 1987;3:61-6.
16. Jörgensen L, Österlin K, Hansen HH, Cooper EH. The prognostic influence of neuron-specific enolase in small-cell lung cancer. Br J Cancer 1988;58:805-7.
17. Gomm SA, Keevil BG, Thatcher N, Hasleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1998;58:797-804.
18. Cooper EH, Prichard J, Bailey CC, Ninane J. Serum neuron-specific enolase in children's cancer. Br J Cancer 1987;56:65-7.
19. Villard JL, Tiget F, Hartmann O. Serum neuron-specific enolase/non-neuronal enolase ratio in diagnosis of neuroblastomas. Cancer 1988;62:2546-53.
20. Karkela J, Bock E, Kaukinen S. CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. Neuro Sci 1993;116:100-9.
21. Beelen MA, Twijnstra A, van der Pol M, Menheere PPCA. Neuron-specific enolase in cerebrospinal fluid of patients with metastatic and non-metastatic neurological disease. Eur J Cancer 1993;29A:193-5.
22. Massabki PS, Oliveira RM, Oda EE, Andrade LEC. Tumor markers in systemic lupus erythematosus and systemic sclerosis. Rev Bras Reumatol 1998;38:215-20.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum 1982;25:1271-7.
25. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
26. American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
27. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis (scleroderma) and localized scleroderma. Arthritis Rheum 1979;22:130-40.
28. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
29. Clements PJ, Lachenbruch PA, Seibold JR, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
30. Pahlman S, Esscher T, Bergvall P, Odelstad L. Purification and characterization of human neuron-specific enolase: radioimmunoassay development. Tumor Biol 1984;5:127-39.
31. Mathieu M, Aubry C, Arthur Y, et al. Societé Francais de Biologie Clinique (SFBC). Commission Enzymologie. Ann Biol Clin 1982;40:163-4.
32. Collazos J, Esteban C, Fernández A, Genollá J. Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases. Am J Respir Crit Care Med 1994;150:143-5.
33. Prados C, Alvarez-Sala R. Clinical evaluation of tumor markers in bronchoalveolar lavage fluid [Spanish]. Med Clin Barc 1994;102:174-7.
34. Sellman M, Ivert T, Ronquist G, Persson L, Semb BKH. Central nervous system damage during cardiac surgery assessed by 3 different biochemical markers in cerebrospinal fluid. Scand J Thor Cardio Surg 1992;26:39-45.
35. Ruibal A, Encabo G, Genollá J, Mañé S, Miralles EM. La enolasa especifica neuronal sérica en pacientes afectos de patología no tumorales. Rev Esp Oncol 1985;32:185-6.
36. Bishop AE, Polak JM, Facer P, Ferri GL, Marangos PJ, Pearse AGE. Neuron specific enolase: A common marker for the endocrinal cells and innervations of the gut and pancreas. Gastroenterology 1982;83:902-15.
37. Scagliotti GV, Gatti E, Michelotto F, Pozzi E. Neuron specific enolase levels in exudative pleural effusions. J Tumor Marker Oncol 1990;5:373-7.
38. Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610-3.
39. Lee P, Norman CS, Sukenik S, Alderdice CA. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985;12:514-7.
40. Lima J, Fonollosa V, Fernández-Cortijo J, et al. Platelet activation and endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991;18:1833-6.
41. Lau CS, McLaren M, Saniabadi A, Belch JJF. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993;22:97-101.
42. Herrick AL, Illingworth K, Blann AD, Hay CRM, Hollis S, Jayson MIV. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
43. Blann AD, Illingworth K, Jayson MIV. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20:1325-30.
44. Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999;31:195-214.
45. Massberg S, Enders G, Leiderer R, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998;92:507-15.
46. Goodfield MJD, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993;84:675-80.
47. Kahaleh MB, Scharstein KK, LeRoy EC. Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets. J Rheumatol 1985;12:468-71.